Theralase Technologies Inc TLTFF
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
Theralase Technologies Inc is focused on the design, development, manufacturing, and sale of patented laser technology platforms used in a wide range of bio-stimulative and bio-destructive clinical applications. The company operates in two divisions: The Photo Dynamic Therapy(PDT) division which is into research and development of Photo Dynamic Compounds for the treatment of cancer and Medical Laser Technology(MLT) division which manufactures products used by healthcare practitioners predominantly for the healing of pain. All of the company revenues were generated from MLT division. The company's products include TLC-1000 Controller, TLC-900 Multiple Probe, TLC-300 Triple Probe, and others.
Toronto, ON, M4B 3G4, Canada